Skip to content
Triangle logo TriangleGet started
← Study library

NCT00720109 · CITED IN SOURCE DOCUMENTS

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2, PHASE3
Status at capture
COMPLETED
Registry last update
2020-04-13

This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy

→

outcome · POSTED

Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events

→

outcome · POSTED

Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy

→

outcome · POSTED

Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation

→

outcome · POSTED

Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Newly diagnosed acute lymphoblastic leukemia (ALL) * Definitive evidence of BCR-ABL fusion (Philadelphia chromosome positive \[PH+\]) from an approved Children's Oncology Group (COG) cytogenetics laboratory * Meets one of the following criteria: * Concurrent enrollment on Clusters of Orthologous Groups (COG)-AALL03B1 (or a successor trial) AND COG-AALL0232, COG-AALL0331, COG-AALL0434 or other front-line COG ALL clinical trial * Concurrent enrollment on COG-AALL03B1 (or a successor trial) AND scheduled to receive a 3 or 4-drug standard induction regimen * Concurrent enrollment on a Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium trial (or scheduled to be treated as per a DFCI Childhood ALL Consortium induction regimen) * All patients must have definitive evidence of BCR-ABL fusion from an approved COG cytogenetics laboratory; patients may NOT have received Day 15 of Induction chemotherapy (or day 18 vincristine if enrolled on a DFCI Childhood ALL Consortium trial) prior to enrollment on AALL0622 * Patients must have a performance status of 0, 1 or 2 at completion of two weeks of Induction; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70mL/min/1.73 m\^2 or maximum serum creatinine based on age and gender as follows: * 0.4 mg/dL (for patients 1 to 5 months of age) * 0.5 mg/dL (for patients 6 to 11 months of age) * 0.6 mg/dL (for patients 1 year of age) * 0.8 mg/dL (for patients 2 to 5 years of age) * 1.0 mg/dL (for patients 6 to 9 years of age) * 1.2 mg/dL (for patients 10 to 12 years of age) * 1.5 mg/dL (males) or 1.4 mg/dL (females) (for patients 13 to 15 years of age) * 1.7 mg/dL (males) or 1.4 mg/dL (females) (for patients \>= 16 years of age) * Total bilirubin =\< 1.5 times upper limit of normal (ULN) for age * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) \< 2.5 times ULN for age * Shortening fraction \>= 27% by echocardiogram or ejection fraction \>= 50% by gated radionuclide study * No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry \> 94% at sea level if there is clinical indication for determination * Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled; however, drugs that induce CYP3A4/5 (carbamazepine, oxcarbazepine, phenytoin, primidone, phenobarbital) should be avoided * Patients will start AALL0622 therapy on day 15 of induction therapy (or day 18 if enrolled on a DFCI Childhood ALL Consortium trial); patients must have received the first 2 weeks of Induction therapy Exclusion Criteria: * Females of childbearing potential must have a negative pregnancy test; patients of childbearing potential must agree to use an effective birth control method * Female patients who are lactating must agree to stop breast-feeding * Patients with Down syndrome * Patients with any clinically significant cardiovascular disease including the following: * Myocardial infarction or ventricular tachyarrhythmia within 6 months * Ejection fraction less than institutional normal * Major conduction abnormality (unless a cardiac pacemaker is present)
healthy Volunteers
false
maximum Age
30 Years
minimum Age
2 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    See Detailed Description
    intervention Names
    1. Drug: Asparaginase
    2. Drug: Cyclophosphamide
    3. Drug: Cytarabine
    4. Drug: Dasatinib
    5. Drug: Daunorubicin Hydrochloride
    6. Drug: Dexamethasone
    7. Drug: Etoposide
    8. Biological: Filgrastim
    9. Drug: Hydrocortisone Sodium Succinate
    10. Drug: Ifosfamide
    11. Other: Laboratory Biomarker Analysis
    12. Drug: Leucovorin Calcium
    label
    Treatment (enzyme inhibitor therapy and chemotherapy)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IT
    name
    Asparaginase
    other Names
    1. ASP-1
    2. Asparaginase II
    3. Asparaginase-E.Coli
    4. Colaspase
    5. Elspar
    6. Kidrolase
    7. L-Asnase
    8. L-ASP
    9. L-asparaginase
    10. L-Asparagine amidohydrolase
    11. Laspar
    12. Lcf-ASP
    type
    DRUG
  2. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  3. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IT or IV
    name
    Cytarabine
    other Names
    1. .beta.-Cytosine arabinoside
    2. 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
    3. 1-.beta.-D-Arabinofuranosylcytosine
    4. 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
    5. 1-Beta-D-arabinofuranosylcytosine
    6. 1.beta.-D-Arabinofuranosylcytosine
    7. 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
    8. 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
    9. Alexan
    10. Ara-C
    11. ARA-cell
    12. Arabine
    type
    DRUG
  4. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given PO
    name
    Dasatinib
    other Names
    1. BMS-354825
    2. Dasatinib Hydrate
    3. Dasatinib Monohydrate
    4. Sprycel
    type
    DRUG
  5. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV
    name
    Daunorubicin Hydrochloride
    other Names
    1. Cerubidin
    2. Cerubidine
    3. Cloridrato de Daunorubicina
    4. Daunoblastin
    5. Daunoblastina
    6. Daunoblastine
    7. Daunomycin hydrochloride
    8. Daunomycin, hydrochloride
    9. Daunorubicin.HCl
    10. Daunorubicini Hydrochloridum
    11. FI-6339
    12. Ondena
    type
    DRUG
  6. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV or PO
    name
    Dexamethasone
    other Names
    1. Aacidexam
    2. Adexone
    3. Aknichthol Dexa
    4. Alba-Dex
    5. Alin
    6. Alin Depot
    7. Alin Oftalmico
    8. Amplidermis
    9. Anemul mono
    10. Auricularum
    11. Auxiloson
    12. Baycadron
    type
    DRUG
  7. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV
    name
    Etoposide
    other Names
    1. Demethyl Epipodophyllotoxin Ethylidine Glucoside
    2. EPEG
    3. Lastet
    4. Toposar
    5. Vepesid
    6. VP 16
    7. VP 16-213
    8. VP-16
    9. VP-16-213
    10. VP16
    type
    DRUG
  8. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV or SC
    name
    Filgrastim
    other Names
    1. G-CSF
    2. Neupogen
    3. r-metHuG-CSF
    4. Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
    5. rG-CSF
    6. Tevagrastim
    type
    BIOLOGICAL
  9. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IT
    name
    Hydrocortisone Sodium Succinate
    other Names
    1. (11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt
    2. A-Hydrocort
    3. Buccalsone
    4. Corlan
    5. Cortisol sodium succinate
    6. Cortop
    7. Efcortelan
    8. Emergent-EZ
    9. Flebocortid
    10. Hidroc Clora
    11. Hycorace
    12. Hydro-Adreson
    type
    DRUG
  10. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV
    name
    Ifosfamide
    other Names
    1. Asta Z 4942
    2. Asta Z-4942
    3. Cyfos
    4. Holoxan
    5. Holoxane
    6. Ifex
    7. IFO
    8. IFO-Cell
    9. Ifolem
    10. Ifomida
    11. Ifomide
    12. Ifosfamidum
    type
    DRUG
  11. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  12. arm Group Labels
    1. Treatment (enzyme inhibitor therapy and chemotherapy)
    description
    Given IV or PO
    name
    Leucovorin Calcium
    other Names
    1. Adinepar
    2. Calcifolin
    3. Calcium (6S)-Folinate
    4. Calcium Folinate
    5. Calcium Leucovorin
    6. Calfolex
    7. Calinat
    8. Cehafolin
    9. Citofolin
    10. Citrec
    11. citrovorum factor
    12. Cromatonbic Folinico
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
63
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed.
    measure
    Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
    time Frame
    At 3 years
  2. description
    Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay)
    measure
    Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
    time Frame
    Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)
secondary Outcomes
  1. description
    Percent of patients MRD Positive (MRD \> 0.01%) at End of Induction.
    measure
    Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
    time Frame
    At the end of induction therapy (at 5 weeks)
  2. description
    A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used.
    measure
    Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
    time Frame
    At end of consolidation (at 11 weeks)
  3. description
    An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death.
    measure
    Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
    time Frame
    From the time entry on study to first event or date of last follow-up, assessed up to 7 years
Full study description
brief Summary
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.
detailed Description
PRIMARY OBJECTIVES: I. To determine the feasibility and toxicity of an intensified chemotherapeutic regimen that incorporates dasatinib for treatment of children, adolescents, and young adults (up to age 30) with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). II. To determine whether the intensification of tyrosine kinase inhibition through the addition of dasatinib in Induction (Days 15-28) and substitution of dasatinib for imatinib during post-Induction therapy, in the context of intensive cytotoxic therapy (according to AALL0031) and a good early response to therapy, will lead to a 3-year event-free survival (EFS) of at least 60% in patients with Ph+ ALL. SECONDARY OBJECTIVES: I. To determine whether the addition of dasatinib during Induction therapy (Days 15-28) will decrease levels of minimal residual disease (MRD) present at end of Induction therapy as compared with COG AALL0031. II. To determine whether early intensified tyrosine kinase inhibitor (TKI) therapy will lower end-Consolidation MRD levels as compared to patients on COG AALL0031 that received imatinib in Consolidation Blocks 1 and 2 (Cohorts 3-5). III. To determine the overall 3-year EFS rate for the whole cohort of Standard- and High-Risk patients treated with dasatinib. IV. To determine the long-term effects of dasatinib on growth, development, and bone metabolism. V. To assess BCR-ABL mutation status at time of diagnosis and progression/relapse. OUTLINE: This is a multicenter study. Patients are stratified according to risk (standard risk vs high risk) at the end of consolidation therapy. INDUCTION THERAPY (weeks 1-4): Patients receive initial induction therapy on days 1-14 prior to beginning the study. Patients then receive vincristine intravenously (IV) and daunorubicin hydrochloride\* IV over 15 minutes on days 15 and 22; dasatinib orally (PO) once daily (QD) and prednisone PO (or methylprednisolone IV) twice daily (BID) on days 15-28; methotrexate intrathecally (IT) on day 29; and some patients receive methotrexate, hydrocortisone, and cytarabine IT on days 15 and 22. After completion of induction therapy, patients undergo bone marrow aspiration for evaluation of disease. Patients with M1 bone marrow and minimal residual disease (MRD) \< 1% (standard-risk disease) proceed to block 1 consolidation therapy 1 week after completion of induction therapy or when blood counts recover (whichever occurs later). Patients with M2 or M3 bone marrow or MRD \>= 1% (high-risk disease) proceed immediately to block 1 consolidation therapy, regardless of blood counts. Patients with clinically evident or biopsy-proven testicular leukemia at diagnosis that persists at the end of induction therapy undergo 12 fractions of testicular radiotherapy beginning within 4 days prior to starting block 1 consolidation therapy. NOTE: \*Patients who receive initial induction therapy on a DFCI Childhood ALL Consortium trial do not receive daunorubicin hydrochloride during induction therapy on this study. CONSOLIDATION THERAPY: BLOCK 1 CONSOLIDATION THERAPY: (weeks 6-8) Patients receive etoposide IV over 1 hour and ifosfamide IV over 1 hour on days 1-5, dasatinib PO on days 1-14 OR on days 1-21, and some patients receive methotrexate, hydrocortisone, and cytarabine IT on days 8 and 15. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV QD beginning on day 6 and continuing until blood counts recover. After completion of block 1 consolidation therapy, patients proceed to block 2 consolidation therapy. BLOCK 2 CONSOLIDATION THERAPY: (weeks 9-11) Patients receive high-dose methotrexate IV continuously over 24 hours on day 1; leucovorin calcium PO or IV every 6 hours for 3 doses on days 2-3; methotrexate, hydrocortisone, and cytarabine IT on day 1; cytarabine IV over 3 hours every 12 hours for 4 doses on days 2 and 3; and dasatinib PO on days 1-14 OR on days 1-21. Patients also receive G-CSF SC or IV QD beginning on day 4 and continuing until blood counts recover. After completion of block 2 consolidation therapy and recovery of blood counts, patients undergo bone marrow aspiration for evaluation of disease. Patients with MRD \< 0.01% (standard-risk disease) with a matched related donor and who are willing to undergo hematopoietic stem cell transplantation (HSCT) proceed to HSCT off study. Standard-risk patients without a suitable donor or those who elect not to undergo HSCT proceed to post-consolidation therapy. Patients with MRD \>= 0.01% (high-risk disease) with a matched related or unrelated donor proceed to HSCT off study. High-risk patients without a suitable donor proceed to post-consolidation therapy. POST-CONSOLIDATION THERAPY: REINDUCTION BLOCK 1 THERAPY: (weeks 12-14) Patients receive vincristine IV on days 1, 8, and 15; daunorubicin hydrochloride IV over 15 minutes on days 1 and 2; cyclophosphamide IV over 1 hour every 12 hours for 4 doses on days 3 and 4; pegaspargase intramuscularly (IM) on day 4; methotrexate, hydrocortisone, and cytarabine IT on days 1 and 15; dexamethasone PO or IV BID on days 1-7 and 15-21; and dasatinib PO on days 1-14 OR on days 1-21. Patients also receive G-CSF SC or IV QD beginning on day 5 and continuing until blood counts recover. After completion of reinduction block 1 therapy, patients proceed to intensification block 1 therapy. INTENSIFICATION BLOCK 1 THERAPY: (weeks 15-23) Patients receive high-dose methotrexate IV continuously over 24 hours on day 1; leucovorin calcium PO or IV every 6 hours for 3 doses on days 2-3; methotrexate, hydrocortisone, and cytarabine IT on days 1 and 22; etoposide IV over 1 hour and cyclophosphamide IV over 1 hour on days 22-26; cytarabine IV over 3 hours every 12 hours for 4 doses on days 43 and 44; asparaginase IM on day 44; and dasatinib PO on days 1-14, 22-35, and 43-56 OR on days 1-63. Patients also receive G-CSF SC or IV QD beginning on day 27 and continuing until blood counts recover. After completion of intensification block 1 therapy, patients proceed to reinduction block 2 therapy. REINDUCTION BLOCK 2 THERAPY: (weeks 24-26) Patients receive reinduction block 2 therapy as per reinduction block 1 therapy. After completion of reinduction block 2 therapy, patients proceed to intensification block 2 therapy. INTENSIFICATION BLOCK 2 THERAPY: (weeks 27-35) Patients receive intensification block 2 therapy as per intensification block 1 therapy. After completion of intensification block 2 therapy, patients proceed to maintenance therapy. MAINTENANCE THERAPY: MAINTENANCE COURSES 1-4: (weeks 36-67) Patients receive high-dose methotrexate IV continuously over 24 hours on day 1; leucovorin calcium PO or IV every 6 hours for 3 doses on days 2-3; methotrexate, hydrocortisone, and cytarabine IT and vincristine IV on days 1 and 29; prednisone PO or IV BID on days 1-5 and 29-33; mercaptopurine PO on days 8-28; methotrexate PO on days 8, 15, and 22; etoposide IV over 1 hour and cyclophosphamide IV over 1 hour on days 29-33; and dasatinib PO on days 1-14 and 29-42 OR on days 1-56. Patients also receive G-CSF SC or IV QD beginning on day 34 and continuing until blood counts recover. Courses repeat every 56 days. After completion of maintenance courses 1-4, patients proceed to maintenance course 5. MAINTENANCE COURSE 5: (weeks 68-75) Patients receive vincristine IV on days 1 and 29; prednisone PO or IV BID on maintenance courses 6-12. MAINTENANCE COURSES 6-12: (weeks 76-131) Patients receive vincristine IV on days 1 and 29; prednisone PO or IV BID on days 1-5 and 29-33; mercaptopurine PO on days 1-56; methotrexate PO on days 1, 8, 15, 22, 29, 36, 43, and 50; and dasatinib PO on days 1-14 and 29-42 OR on days 1-56. Courses repeat every 56 days. Patients long-term growth, development, and bone metabolism are assessed after completion of study therapy and then annually for 5 years. After completion of study therapy, patients are followed up periodically for up to 10 years.
Source references
references
  1. citation
    Tasian SK, Peters C. Targeted therapy or transplantation for paediatric ABL-class Ph-like acute lymphocytic leukaemia? Lancet Haematol. 2020 Dec;7(12):e858-e859. doi: 10.1016/S2352-3026(20)30369-0. No abstract available.
    pmid
    33242441
    type
    DERIVED
  2. citation
    Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, Chang BH, Mullighan C, Iacobucci I, Silverman LB, Borowitz MJ, Carroll AJ, Heerema NA, Gastier-Foster JM, Wood BL, Mizrahy SL, Merchant T, Brown VI, Sieger L, Siegel MJ, Raetz EA, Winick NJ, Loh ML, Carroll WL, Hunger SP. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018 Aug 1;36(22):2306-2314. doi: 10.1200/JCO.2017.76.7228. Epub 2018 May 29.
    pmid
    29812996
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-df117c259087dc7be7c5
      requested nct id
      NCT00720109
      primary nct id
      NCT00720109
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      8416f6a719c496873bd76f9837e64f45de187c289bc5ec0bf994c3e18f233983
      payload sha256
      05ad337950a27f6d6e4f76314cdc972227a8a1008373d247598aed4a9b2a756c
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-df117c259087dc7be7c5
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00720109
      occurrences
      1. context exact
        n = 13).</li><li>Patients with additional cytogenetic abnormalities had worse outcomes (<em>P</em> = .05).</li></ul></div></li><li>The <a href="/clinicaltrials/NCT00720109">COG-AALL0622 (NCT00720109)</a> study tested the use of dasatinib (instead of imatinib) combined with a chemotherapy backbone similar to that used in the COG-A
        end
        832582
        exact text
        NCT00720109
        start
        832571
      2. context exact
        ith additional cytogenetic abnormalities had worse outcomes (<em>P</em> = .05).</li></ul></div></li><li>The <a href="/clinicaltrials/NCT00720109">COG-AALL0622 (NCT00720109)</a> study tested the use of dasatinib (instead of imatinib) combined with a chemotherapy backbone similar to that used in the COG-AALL0031 trial.[<a href="#ci
        end
        832609
        exact text
        NCT00720109
        start
        832598
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/346ccc02fe964bb078.html
      source file sha256
      8416f6a719c496873bd76f9837e64f45de187c289bc5ec0bf994c3e18f233983
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:53.377184+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      d68ab4be374e916e0de9c7632347ccef2167b36c83a023ce62cc9bb0575973b9
      source title
      Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 21, 2025
        datetime
        2025-04-21T12:00:00Z
        display
        April 21, 2025

    Preserved source evidence · Not medical advice